

Tablica 11.1. Prvih 30 lijekova prema financijskoj potrošnji izraženo u kunama u 2020. godini, na teret HZZO-a

RBR	ATK	INN	UKUPNI IZNOS
1	L01XC18	pembrolizumab	240.837.836
2	L01XC13	pertuzumab	124.788.209
3	V06DX03	namirnice za enteralnu primjenu	124.744.431
4	L01XC07	bevacizumab	124.112.106
5	L01XE27	ibrutinib	110.972.124
6	B01AF01	rivaroksaban	109.378.332
7	L01XC03	trastuzumab	101.679.571
8	N05AX13	paliperidon	90.189.028
9	L01XC24	daratumumab	79.588.231
10	A02BC02	pantoprazol	79.018.144
11	L01XC32	atezolizumab	75.749.813
12	C10AA05	atorvastatin	71.406.753
13	J06BA02	imunoglobulini, humani, za i.v. primjenu	69.349.494
14	M09AX07	nusinersen	67.527.568
15	L01XC17	nivolumab	65.255.525
16	B01AE07	dabigatran eteksilat	61.837.578
17	L02BX03	abirateron	58.794.851
18	L01XE42	ribociklib	58.572.145
19	L02BB04	enzalutamid	57.156.172
20	M01AE01	ibuprofen	56.688.945
21	L01XC02	rituksimab	55.196.975
22	L04AX04	lenalidomid	54.888.673
23	C09BX01	perindopril, amlodipin i indapamid	54.553.633
24	L04AB04	adalimumab	54.246.908
25	L01XE33	palbociklib	51.345.544
26	L04AA36	okrelizumab	47.539.882
27	B01AF02	apiksaban	47.448.760
28	C07AB07	bisoprolol	47.324.257
29	L04AB02	infliksimab	47.205.692
30	C09DX04	valsartan i sakubitril	43.459.726